| Identification | Back Directory | [Name]
FLURITHROMYCIN | [CAS]
82664-20-8 | [Synonyms]
cl-932
p80206
C1-932
P-0501-A
FLURITHROMYCIN
fluritromicina
antibioticp80206
Huritromicina(sp)
8-fluoro-erythromyci
8-fluoroerythromycin
8-FluoroerythroMycin A
FLURITHROMYCIN USP/EP/BP
(8s)-8-fluoroerythromycina
Erythromycin, 8-fluoro- (9CI) | [Molecular Formula]
C37H66FNO13 | [MDL Number]
MFCD01939586 | [MOL File]
82664-20-8.mol | [Molecular Weight]
751.92 |
| Chemical Properties | Back Directory | [Melting point ]
>139°C (dec.) | [Boiling point ]
814.6±65.0 °C(Predicted) | [density ]
1.22±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under inert atmosphere | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.94±0.70(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Chemical Properties]
Obtained as prismatic crystals from ethanol, melting point 183-184°C [α]D-54.9°. UV maximum absorption: 283nm (ε17.9). | [Uses]
A fluorinated derivative of Erythromycin (E649950). A macrolide antibiotic. | [Definition]
ChEBI: An erythromycin derivative that is erythromycin A in which the hydrogen attached to the carbon at position 8 (alpha to the ketone carbonyl group) has been replaced by a fluorine. It has been used (generally as the corresponding monoethyl s
ccinate ester) as an antibacterial drug. | [Pharmaceutical Applications]
A semisynthetic derivative of erythromycin A, supplied for oral administration. It is stable at acid pH due to the presence of the fluorine atom at C-8 of the erythronolide A ring.
It is active against most streptococci (including Str. pneumoniae and Str. agalactiae; MIC50 0.03 mg/L), Mor. catarrhalis, N. gonorrhoeae (MIC50 0.04 mg/L), C. trachomatis (MIC 0.06– 0.125 mg/L), M. genitalium (MIC50 0.007 mg/L) and U. urealyticum (MIC50 0.03 mg/L). It has little or no activity against H. influenzae and M. hominis. Activity against anaerobes is similar to that of erythromycin A. It displays cross-resistance with erythromycin A.
A single 500 mg oral dose achieved a mean peak plasma concentration of 1.2–2 mg/L after 1–2 h. The apparent elimination half-life was 8 h and the volume of distribution 5.5 L/ kg. With repeated doses (500 mg orally every 8 h for 10 doses), plasma concentrations were 0.72 mg/L immediately before and 0.67 mg/L at 4 h after the last dose. Absorption is not significantly affected by food. After administration of a single 375 mg tablet of flurithromycin ethylsuccinate, the mean serum levels at 0.5 h were 0.43 ± 0.35 mg/L. The mean peak serum concentration (1.41 ± 0.49 mg/L) was achieved at 1 h. At 8 and 12 h, the serum levels were 0.14 (± 0.05) and 0.04 (± 0.04) mg/L, respectively. The apparent elimination half-life is 3.94 (± 1.42) h. The apparent half-life in artificial gastric juice was about 40 min.
It is generally well tolerated and has been used successfully for the treatment of lower respiratory tract infections. Availability is limited. |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
Energy Chemical
|
| Telephone: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|